newsfilter
← Latest News
Business Wire·

iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial

First infant treated in the low-dose cohort achieved durable clinical response with sustained discontinuation of standard-of-care therapies, and no hyperammonemic events (HAEs) reported in the 18 months following